Swedish Orphan Biovitrum ABSWOBY 67 PB Ratio is 3.70 as of Jun. 25, 2026, which is 24% above its 10-year median of 2.99. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.17 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 77.33% on this metric.
Swedish Orphan Biovitrum AB stock PB Ratio (=3.77) is close to 5-year high of 3.83.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's PB Ratio or its related term are showing as below:
SWOBY'
s PB Ratio Range Over the Past 10 Years
Min: 1.9 Med: 2.99 Max: 9.99
Current: 3.77
During the past 13 years, Swedish Orphan Biovitrum AB's highest PB Ratio was 9.99. The lowest was 1.90. And the median was 2.99.
SWOBY's PB Ratio is ranked worse than 77.33% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs SWOBY: 3.77
During the past 12 months, Swedish Orphan Biovitrum AB's average Book Value Per Share Growth Rate was 2.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 23.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Swedish Orphan Biovitrum AB was 42.30% per year. The lowest was -13.00% per year. And the median was 13.60% per year.
Back to Basics: PB Ratio
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Swedish Orphan Biovitrum AB PB Ratio Related Terms
Swedish Orphan Biovitrum AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Swedish Orphan Biovitrum AB (SWOBY) has a PB Ratio of 3.70 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 24% above median its historical median of 2.99. Over the past decade, Swedish Orphan Biovitrum AB's PB Ratio has ranged from 1.90 to 9.99. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #713 out of 922 companies in the Drug Manufacturers industry, placing it in the top 77.3%.
Is Swedish Orphan Biovitrum AB's PB Ratio too high?
Swedish Orphan Biovitrum AB's current PB Ratio of 3.70 is 24% above median its 10-year median of 2.99. Over the past 10 years, this metric has ranged from a low of 1.90 to a high of 9.99. The Drug Manufacturers industry median PB Ratio is 1.88. Swedish Orphan Biovitrum AB's value of 3.70 is 96.8% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #713 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #713 out of 922 companies for PB Ratio. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median PB Ratio is 1.88. Swedish Orphan Biovitrum AB's value of 3.70 is 96.8% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own PB Ratio has ranged from 1.90 to 9.99 over the past decade. While the company's 10-year median is 2.99 vs. the industry median of 1.88, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current PB Ratio of 3.70 is 96.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current PB Ratio is 3.70, which is 24% above median its own 10-year median of 2.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current PB Ratio is 3.70, which is 24% above median its 10-year median of 2.99 and 96.8% above the Drug Manufacturers industry median of 1.88. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current PB Ratio is 3.70 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
PB Ratio: 3.70 (24% above median its 10-year median of 2.99)
GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
Industry Position: 96.8% above the Drug Manufacturers median (#713 of 922)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
